Stock A328130 LUNIT INC.
Add to a list
To use this feature you must be a member
Log inSign up

Lunit Inc. Stock

Equities

A328130

KR7328130000

Advanced Medical Equipment & Technology

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
52,300 KRW -2.61% Intraday chart for Lunit Inc. +6.73% -36.14%
Apr. 16 Lunit Wins Shareholder Approval for Volpara Health Takeover MT
Apr. 12 Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover MT

Financials

Sales 2024 * 53.55B 38.93M Sales 2025 * 96.38B 70.06M Capitalization 1,504B 1.09B
Net income 2024 * -15B -10.9M Net income 2025 * 12B 8.72M EV / Sales 2024 * 24.9 x
Net cash position 2024 * 170B 124M Net cash position 2025 * 180B 131M EV / Sales 2025 * 13.7 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.43%
More Fundamentals * Assessed data

Chart Lunit Inc.

Dynamic Chart

Latest news about Lunit Inc.

Lunit Wins Shareholder Approval for Volpara Health Takeover MT
Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover MT
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals CI
Lunit Announces Publication of New Study Featuring Lunit SCOPE IO CI
Lunit Announces Two Commercial Deals Signal its Expansion in Europe CI
Lunit Inc. Receives Two Supply Contracts That Mark Its Strategic Expansion into the East and Southeast Asian Region CI
Lunit Announces Three-Year Supply Contract with Samsung Electronics CI
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment MT
Lunit to Take Over Volpara Health; Lunit Shares Decline 4% MT
Lunit Inc. agreed to acquire Volpara Health Technologies Limited from Harbour Asset Management Limited and others for AUD 300 million. CI
Lunit Inc. Partners with NTT DATA Singapore to Introduce Lunit Insight CXR to Singapore's Public Healthcare System CI
Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology CI
Lunit Announces to Unveil Eight Groundbreaking Abstracts At the Radiological Society of North America CI
Lunit Inc. Receives U.S. Food and Drug Administration 510(K) Clearance for its 3D Breast Tomosynthesis Ai Solution, Lunit Insight DBT CI
Lunit Expands Reach of Its AI-Powered Chest Screening Solution to Global Military Health Institutions CI
More news

Press releases Lunit Inc.

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients AQ
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment, New Study in Breast Cancer Research AQ
Lunit Presents Seven Study Results at ECR 2024, Showcasing AI's Robust Performance in Diverse Clinical Settings AQ
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy across Diverse Tumors, published in the JITC AQ
Lunit INSIGHT CXR Excels in Long Nodule Detection, Exceptional Performance in Head-to-Head Study published in Radiology AQ
More press releases

Quotes and Performance

1 day-2.61%
1 week+6.73%
Current month-11.36%
1 month-13.27%
3 months-25.29%
6 months-25.82%
Current year-36.14%
More quotes

Highs and lows

1 week
49 350.00
Extreme 49350
56 500.00
1 month
47 150.00
Extreme 47150
61 900.00
Current year
47 150.00
Extreme 47150
82 800.00
1 year
24 875.00
Extreme 24875
139 750.00
3 years
9 450.00
Extreme 9450
139 750.00
5 years
9 450.00
Extreme 9450
139 750.00
10 years
9 450.00
Extreme 9450
139 750.00
More quotes

Managers and Directors - Lunit Inc.

Managers TitleAgeSince
Beom-Seok Suh CEO
 Chief Executive Officer 41 15-12-31
Jung-Min Lee FOU
 Founder - 13-08-23
Seung-Wook Baek FOU
 Founder 41 13-08-23
Members of the board TitleAgeSince
Garheng Kong BRD
 Director/Board Member 49 21-10-31
Seung-Wook Baek FOU
 Founder 41 13-08-23
Beom-Seok Suh CEO
 Chief Executive Officer 41 15-12-31
More insiders

ETFs positioned on Lunit Inc.

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
More ETFs positioned on Lunit Inc.

Quotes

Date Price Change Volume
24-04-26 52,300 -2.61% 353,041
24-04-25 53,700 -0.19% 180,508
24-04-24 53,800 +1.89% 389,753
24-04-23 52,800 -1.68% 239,403
24-04-22 53,700 +9.59% 347,425

End-of-day quote Korea S.E., April 25, 2024

More quotes

Company Profile

Lunit Inc is a Korea-based company principally engaged in the development and supply of medical software. The Company is principally engaged in the development and supply of medical software such as cancer diagnostic aid solutions, cancer early detection solutions, cancer risk prediction solutions and others through artificial intelligence (AI) technologies.
Sector
Advanced Medical Equipment & Technology
Calendar
2024-08-10 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Lunit Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
52,300 KRW
Average target price
100,000 KRW
Spread / Average Target
+91.20%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

1st Jan change Capi.
LUNIT INC. Stock Lunit Inc.
-36.14% 1.09B
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.47B
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.45B
SECTRA AB Stock Sectra AB
+22.93% 3.89B
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.15B
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.28B
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 893M
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 902M
VERADIGM INC. Stock Veradigm Inc.
-24.12% 857M
SURGICAL SCIENCE SWEDEN AB Stock Surgical Science Sweden AB
-18.47% 693M
Medical Software & Technology Services
  1. Stock Market
  2. Equities
  3. A328130 Stock